Dr. Ana Maria Abreu-Velez remembers Arturo Ramírez (Names changed for privacy) as “a very sweet man” who was always on time for his appointments with her.
He always wore a clean shirt, a wide smile and a big hat to protect him from the relentless sun that is synonymous with the jungles of El Bagre, Colombia in South America, where he and his family of Indian Natives lived. Arturo suffered from what the scientists call endemic pemphigus foliaceus (EPF). It stalks Colombia like the deadly Coral snakes frequently found in the jungle.
Dr. Abreu-Velez is a native of Colombia and in 2002 was doing research sup-ported by a number of local, state and international agencies. She now teaches and conducts research into the causes of autoimmune skin diseases at the Georgia Med-i cal College in Augusta, Georgia.
A clean shirt and an unfailing on-time record are rare in the jungle. They demonstrate just how much Arturo valued his visits with Dr. Abreu-Velez, who did what she could to treat his illness with the woefully inadequate medical facilities and supplies available. He was cautioned to stay out of the sun, which is known to aggravate the disease, but this was simply an impossible request.
This disease is a persistent, painful, tragic and on-going mystery. Among many mystifying facts are that, unlike pemphigus everywhere else in the world, EPF is far from a rare disease. It is found in up to 30% of some villages, and frequently runs in families. In fact, EPF had already claimed Arturo’s brother, two brothers-in-law and many others of Arturo’s Zenu Indian tribe.
EPF is mystifying for other reasons. Like pemphigus, genetic markers are found in many people; but in spite of all the tools of
science and decades of study by scientists, no one has a clue about what triggers the lesions that eventually cover a patient’s body. Antibodies of EPF are found in the blood up to 7 years in advance of the outbreak of blisters, but nothing under the sun can stop them.
It is most likely caused by something in the environment, because patients who leave the endemic areas recover, and those who return suffer relapse.
“When I came to the United States in 2002, I had about 150 active cases (of endemic pemphigus), plus about 600 relatives and hundreds of controls (people without signs of the disease) in the community. In my private practice and at the hospital, I was able to bring together almost a hundred patients with pemphigus, pemphigoid and other genetic and acquired blistering diseases. All these people became part of our pemphigus family,” said Abreu-Velez.